ArticlePloS one2016
A Novel Admixture-Based Pharmacogenetic Approach to Refine Warfarin Dosing in Caribbean Hispanics.
Article in PloS one, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Pharmacogenetics of Warfarin in Puerto Rican Patients Using a Physiogenomics Approach.
A Randomized, Double-blind Clinical Trial of Anticoagulation Therapy With Warfarin in Caribbean Hispanics: Comparison Between an Admixture-adjusted Pharmacogenetic-driven Warfarin Dose Refinement Algorithm and the Standard of Care
Who cites it
21 citing papers in PubMed, 36 citations in OpenAlex.
- Prospective validation of the International Warfarin Pharmacogenetics Consortium algorithm in high-risk elderly people (VIALE study).The pharmacogenomics journal · 2020Trial
- Low-frequency variants at thePharmacogenomics · 2019Trial
- Leveraging Machine Learning to Predict Warfarin Sensitivity in the Puerto Rican Population: A Pharmacogenomic Approach.International journal of environmental research and public health · 2026Article
- Addressing genetic diversity and health inequities: RELIVAF's proposal for Latin American pharmacogenomic guidelines.Frontiers in pharmacology · 2026Review
- Machine Learning for Warfarin Therapy: A Systematic Review.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Local Ancestry-Informed Candidate Pathway Analysis of Warfarin Stable Dose in Latino Populations.Clinical pharmacology and therapeutics · 2023Article
- Genetic Ancestry Inference and Its Application for the Genetic Mapping of Human Diseases.International journal of molecular sciences · 2021Review
- Functional Assessment of 12 Rare AllelicJournal of personalized medicine · 2021Article
- Multi-site Investigation of Genetic Determinants of Warfarin Dose Variability in Latinos.Clinical and translational science · 2021Article
- Machine Learning for Prediction of Stable Warfarin Dose in US Latinos and Latin Americans.Frontiers in pharmacology · 2021Article
- Insight on the Genetics of Atrial Fibrillation in Puerto Rican Hispanics.Stroke research and treatment · 2021Article
- Beyond drugs: the evolution of genes involved in human response to medications.Proceedings. Biological sciences · 2019Article
- Machine Learning Algorithm for Predicting Warfarin Dose in Caribbean Hispanics Using Pharmacogenetic Data.Frontiers in pharmacology · 2019Article
- CYP2C9*61, a rare missense variant identified in a Puerto Rican patient with low warfarin dose requirements.Pharmacogenomics · 2019Article
- Precision medicine: does ethnicity information complement genotype-based prescribing decisions?Therapeutic advances in drug safety · 2018Review
- Creating and validating a warfarin pharmacogenetic dosing algorithm for Colombian patients.Pharmacogenomics and personalized medicine · 2018Article
- Cost-Utility Study of Warfarin Genotyping in the VACHS Affiliated Anticoagulation Clinic of Puerto Rico.Puerto Rico health sciences journal · 2017Article
- Warfarin Pharmacogenomics in Diverse Populations.Pharmacotherapy · 2017Review
- Warfarin Anticoagulation Therapy in Caribbean Hispanics of Puerto Rico: A Candidate Gene Association Study.Frontiers in pharmacology · 2017Article
- STRATEGIES FOR EQUITABLE PHARMACOGENOMIC-GUIDED WARFARIN DOSING AMONG EUROPEAN AND AFRICAN AMERICAN INDIVIDUALS IN A CLINICAL POPULATION.Pacific Symposium on Biocomputing. Pacific Symposium on Biocomputing · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 4 institutions in 2 countries.
Funding
Abstract
aimThis study is aimed at developing a novel admixture-adjusted pharmacogenomic approach to individually refine warfarin dosing in Caribbean Hispanic patients. PATIENTS &
methodsA multiple linear regression analysis of effective warfarin doses versus relevant genotypes, admixture, clinical and demographic factors was performed in 255 patients and further validated externally in another cohort of 55 individuals.
resultsThe admixture-adjusted, genotype-guided warfarin dosing refinement algorithm developed in Caribbean Hispanics showed better predictability (R2 = 0.70, MAE = 0.72mg/day) than a clinical algorithm that excluded genotypes and admixture (R2 = 0.60, MAE = 0.99mg/day), and outperformed two prior pharmacogenetic algorithms in predicting effective dose in this population. For patients at the highest risk of adverse events, 45.5% of the dose predictions using the developed pharmacogenetic model resulted in ideal dose as compared with only 29% when using the clinical non-genetic algorithm (p<0.001). The admixture-driven pharmacogenetic algorithm predicted 58% of warfarin dose variance when externally validated in 55 individuals from an independent validation cohort (MAE = 0.89 mg/day, 24% mean bias).
conclusionsResults supported our rationale to incorporate individual's genotypes and unique admixture metrics into pharmacogenetic refinement models in order to increase predictability when expanding them to admixed populations like Caribbean Hispanics.
trial registrationClinicalTrials.gov NCT01318057.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.